Neurim Pharmaceuticals (Neurim) announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending an extension to the existing indication to include the treatment of insomnia in children with neurogenetic disorders (NGDs).